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Tissue-type plasminogen activator (t-PA) is a pivotal en-
zyme in the mammalian fibrinolytic system. It exerts its
action by converting the zymogen plasminogen into the
proteolytically active serine protease plasmin, which, in turn,
degrades fibrin clots. Because of its affinity for fibrin, t-PA
is the prototypic fibrin-specific plasminogen activator (1).
This specificity and its lack of antigenicity have made it a
powerful tool in the treatment of acute myocardial infarc-
tion (2). The t-PA is inactivated by its suicide substrate,
plasminogen activator inhibitor-1 (PAI-1) (3).
Storage of t-PA in endothelial cells. The t-PA is synthe-
sized and stored in endothelial cells and vascular neurons
(4,5). There has been much controversy in the published
data regarding the specific endothelial cell vesicle in which
t-PA is stored. It has been suggested that because t-PA is
often released concomitantly with von Willebrand factor
(vWF), both proteins are stored in Weibel-Palade bodies.
Emeis et al. (6) demonstrated that this is not necessarily the
case. In studies using rat lung homogenates fractionated by
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density gradient centrifugation, particles containing a ma-
jority of the t-PA antigen and activity were found at similar
densities in sucrose and Nycodenz gradients. The Nycodenz
gradient co-localized t-PA granules with vWF containing
Weibel-Palade bodies. However, the two proteins fraction-
ated at different densities in sucrose. Using double-
immunofluorescence staining of human umbilical vein en-
dothelial cells, t-PA and vWF particles did not co-localize
(6). Further evidence that t-PA and vWF are stored in
separate granules is based on the observation that these
proteins are differentially released by specific stimuli. For
example, ionomycin-induced vWF release is dose-
dependent and correlates with the increase in intracellular
calcium concentration. In contrast, t-PA is not released
until the calcium concentration exceeds a threshold of 500
nM (7). Thus, it appears that t-PA and vWF vesicles
fractionate at different densities, do not co-localize by
immunofluoroscopy, and can be induced to be released
separately.
Molecular mechanisms of t-PA release. In vitro studies of
t-PA release have revealed much about the signal transduc-
tion pathways involved in its release. Early studies revealed
that constitutive release of t-PA from the endothelium can
be augmented in a dose- and time-dependent manner by
protein kinase C (PKC) activation. In PKC-activated cells,
cyclic adenosine monophosphate (cAMP) agonists augment
t-PA secretion (8). Furthermore, PKC-augmented t-PA
secretion is dependent on an increase in t-PA message (9).
However, these studies examined t-PA secretion over peri-
ods of hours to days, not minutes.
Subsequently, a cell culture model of t-PA release was
developed. In this model, it was found that t-PA is both
constitutively secreted and can be released rapidly in a
dose-dependent manner in response to agonists such as
thrombin, isoproterenol, and prostacyclin. It was discovered
that these agonists act in a dose-dependent manner, and
preincubation of cells with sodium butyrate or retinoic acid
amplifies the response to stimulation with agonists (10).
Little is known about the precise molecular mechanisms
by which bradykinin induces t-PA release. It has been
suggested that thrombin and prostacyclin induce t-PA
release through independent G-protein–signaling pathways
(7,11). Prostacyclin and isoproterenol couple Gs and likely
signal through cAMP, whereas thrombin, which couples
Gq, likely signals through calcium-dependent pathways.
The thrombin receptor couples G12, Gi, and Gq. The Gi,
which inhibits adenylyl cyclase, and G12, which signals
through Rho, seem unlikely candidates in facilitating t-PA
release. Gq, which generates inositol triphosphate through
phospholipase C-beta (PLC-beta), inducing intracellular
calcium shifts, appears to be a likely downstream target. The
G-protein subunits beta and gamma, which also activate
PLC-beta, may also be responsible for these calcium effects
(12). Furthermore, coupling of the thrombin receptor to Gi
may explain the variable effects of pertussis toxin on t-PA
release in the presence and absence of calcium (7).
In vivo studies of t-PA release. As alluded to earlier, t-PA
release from endothelial cells is an area of much interest, as
it is a distinct marker of endothelial function. Studies of in
vivo t-PA release have revealed much about the mechanics
of this phenomenon, as both endothelial-dependent ago-
nists such as methacholine and endothelial-independent
agonists such as isoproterenol induce rapid release of t-PA,
independent of effects on vessel wall relaxation (13). In
addition to these agonists, bradykinin was also found to
induce t-PA release and increase flow in both the human
forearm and coronary artery bed (14,15). Bradykinin-
induced t-PA release is a bradykinin type-2 receptor (B2)-
mediated phenomenon, as HOE-140, a specific B2 receptor
antagonist, blocks bradykinin-mediated t-PA release. Be-
cause B2 stimulation results in prostacyclin and nitric oxide
generation, it was hypothesized that inhibition of synthesis
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of these products with indomethacin, a nonselective cyclo-
oxygenase inhibitor, and L-NG-monomethyl-L-arginine (L-
NMMA), an inhibitor of nitric oxide synthase, would
prevent t-PA release from the vascular bed. However,
neither indomethacin nor L-NMMA, alone or in combina-
tion, inhibited bradykinin-induced t-PA release. This led to
the hypothesis that it may be either an endothelial-derived
hyperpolarization factor-mediated phenomenon or perhaps
a calcium-mediated phenomenon, as the B2 receptor cou-
ples to the Gq/PLC-beta/calcium-signaling pathway (16).
Because bradykinin is rapidly degraded by angiotensin-
converting enzyme (ACE), one would anticipate that ACE
inhibition would augment bradykinin-induced t-PA. Treat-
ment with quinapril enhanced bradykinin-induced t-PA
release in the human forearm, whereas losartan, an angio-
tensin II type-1 receptor blocker, had no effect. Substance
P–mediated t-PA release, however, was not augmented by
treatment with quinapril or losartan. Labinjoh et al. (17)
suspected that some of the beneficial clinical effects of ACE
inhibitors may be the result of enhancement of bradykinin-
mediated t-PA release.
In humans, t-PA release in response to bradykinin or
Substance-P is impaired in smokers, both in the coronary
vasculature and forearm (18,19). Methacholine-induced
t-PA release is unchanged in borderline hypertensive sub-
jects (20). Other conditions associated with impaired endo-
thelial vasodilator function, such as hypercholesterolemia
and diabetes, have not been specifically studied for their
impact on arterial t-PA release in response to bradykinin or
substance P.
In this issue of the Journal, Witherow et al. (21) examined
the effects of ACE inhibition on t-PA release in subjects
with ischemic cardiomyopathy. The highlight of this study
is the extremely robust response to bradykinin in the
presence of ACE inhibition; this response was 4.5-fold
greater than that seen in subjects without ischemic cardio-
myopathy. The authors describe transient t-PA increases
that approach those seen when t-PA is administered for
acute myocardial infarction. This augmented response may
reflect therapeutic effects of ACE inhibition in individuals
whose neurohormonal axis has been perturbed by heart
failure.
Questions that arise from this work include the effects of
bradykinin on the presumably diseased coronary bed of
subjects with ischemic cardiomyopathy. The coronary vas-
culature in these subjects will likely have a greater plaque
burden than that seen in the forearm, more local ACE
activity, reduced local bradykinin concentrations, and pre-
sumably upregulated B2 receptors. This environment would
seem predisposed to an augmented response to ACE
inhibition and exogenous bradykinin. Although there was
no difference between losartan and placebo in the previous
study of normal subjects, angiotensin II may play a larger
role in the fibrinolytic balance of patients with heart failure,
by stimulating PAI-1 expression. This study has, for the
first time, to the best of our knowledge, shown that ACE
inhibition augments bradykinin-induced t-PA release in
patients with known cardiovascular disease. Although many
drugs have been reported to improve endothelial-dependent
vasodilation, much less is known about the clinical factors
that impair endothelial t-PA release or therapies that restore
this important function. Furthermore, it is possible that
t-PA release may be a critical aspect of endothelial function
in terms of preventing coronary thrombosis. Studies such as
Witherow et al. (21) are likely to lead to a more comprehensive
perspective of the complexities of endothelial function.
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